Impact Factor 4.400

The 1st most cited open-access journal in Pharmacology & Pharmacy

Correction ARTICLE

Front. Pharmacol., 05 December 2016 | https://doi.org/10.3389/fphar.2016.00468

Corrigendum: Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale”

Sabrina C. Cecere1, Sabrina Rossetti1, Carla Cavaliere2, Chiara Della Pepa1, Marilena Di Napoli1, Anna Crispo3, Gelsomina Iovane1, Raffaele Piscitelli4, Domenico Sorrentino5, Gennaro Ciliberto6, Piera Maiolino4, Paolo Muto7, Sisto Perdonà5, Massimiliano Berretta8, Sandro Pignata1, Gaetano Facchini1* and Carmine D'Aniello9
  • 1Division of Medical Oncology, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale,” Naples, Italy
  • 2Department of Onco-Ematology Medical Oncology, S.G. Moscati Hospital of Taranto, Taranto, Italy
  • 3Unit of Epidemiology, Struttura Complessa di Statistica Medica, Biometria e Bioinformatica, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale,” Naples, Italy
  • 4Pharmacy Unit, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale,” Naples, Italy
  • 5Division of Urology, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale,” Naples, Italy
  • 6Scientific Direction, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale,” Naples, Italy
  • 7Division of Radiation Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale,” Naples, Italy
  • 8Division of Medical Oncology–Centro di Riferimento Oncologico, Aviano, Italy
  • 9Oncology Unit, A.O.R.N. dei COLLI “Ospedali Monaldi-Cotugno-CTO,” Naples, Italy

A corrigendum on
Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale”

by Cecere, S. C., Rossetti, S., Cavaliere, C., Della Pepa, C., Di Napoli, M., Crispo, A., et al. (2016). Front. Pharmacol. 7:287. doi: 10.3389/fphar.2016.00287

In the original article, we have neglected to thank our funder, Novartis Farma S.p.A. The Funding Statement appears below.

Funding

Novartis Farma S.p.A. supported publication of this article.

The authors apologize for this oversight. This error does not change the scientific conclusions of the article in any way.

Conflict of Interest Statement

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Keywords: pazopanib, metastatic renal cancer, real world, angiogenesis inhibitors, treatment

Citation: Cecere SC, Rossetti S, Cavaliere C, Della Pepa C, Di Napoli M, Crispo A, Iovane G, Piscitelli R, Sorrentino D, Ciliberto G, Maiolino P, Muto P, Perdonà S, Berretta M, Pignata S, Facchini G and D'Aniello C (2016) Corrigendum: Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale.” Front. Pharmacol. 7:468. doi: 10.3389/fphar.2016.00468

Received: 10 October 2016; Accepted: 18 November 2016;
Published: 05 December 2016.

Edited and reviewed by: Giovanni Li Volti, University of Catania, Italy

Copyright © 2016 Cecere, Rossetti, Cavaliere, Della Pepa, Di Napoli, Crispo, Iovane, Piscitelli, Sorrentino, Ciliberto, Maiolino, Muto, Perdonà, Berretta, Pignata, Facchini and D'Aniello. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Gaetano Facchini, gafacchi@libero.it